The success of Sildenafil initially fueled a period of growth for major pharmaceutical companies, but recent shifts present a uncertain scenario for investors. Generic competitors are reducing earnings, and ongoing https://haleematadd028658.full-design.com/the-blue-pill-and-big-pharma-a-volatile-play-83786528